Ramucirumab (Synonyms: LY3009806) |
| Catalog No.GC19534 |
라무시루맙은 고형 종양 치료를 위한 인간 VEGFR-2 길항제입니다. 라무시루맙은 VEGFR-2의 세포외 결합 도메인에 결합하고 VEGFR 리간드인 VEGF-A, VEGF-C 및 VEGF-D의 결합을 방지하는 재조합 인간 면역글로불린 G1 단일클론 항체입니다. Ramucirumab은 또한 혈관 신생 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 947687-13-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ramucirumab is a fully human monoclonal antibody (IgG1). Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *